Corbus Pharmaceuticals (NASDAQ:CRBP) versus Shineco (NASDAQ:SISI) Financial Comparison

Corbus Pharmaceuticals (NASDAQ:CRBP) and Shineco (NASDAQ:SISI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Corbus Pharmaceuticals and Shineco, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	8	1	2.73
Shineco	1	0	0	0	1.00

Corbus Pharmaceuticals presently has a consensus price target of $44.38, indicating a potential upside of 294.44%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Shineco.

Institutional & Insider Ownership

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.1% of Shineco shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Shineco shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500. Comparatively, Shineco has a beta of -0.91, meaning that its share price is 191% less volatile than the S&P 500.

Valuation and Earnings

This table compares Corbus Pharmaceuticals and Shineco”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$40.21 million	($5.51)	-2.04
Shineco	$9.60 million	0.02	-$22.45 million	($204.00)	0.00

Shineco has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corbus Pharmaceuticals and Shineco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-43.65%	-39.62%
Shineco	-380.55%	-79.89%	-33.01%

Summary

Corbus Pharmaceuticals beats Shineco on 10 of the 14 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.